Time for a Turnaround at Teva Pharmaceuticals Industries Ltd?

Are Teva's management and patent woes finally a thing of the past?

Feb 3, 2014 at 6:30PM

Drugmaker Teva Pharmaceuticals (NYSE:TEVA) has had a few rocky years in an industry that has soared over the same period. The $38 billion generic pharmaceutical copmany has faced some serious management debacles and a looming patent expiration.

TEVA Chart

Teva Pharmaceuticals data by YCharts.

2014 has brought a glimmer of hope to the embattled company, but can new management and an improved blockbuster fend off competition from Biogen Idec (NASDAQ:BIIB) and Mylan (NASDAQ:MYL)?

He did what??
When former CEO Jeremy Levin signed on to head Teva in 2012, he knew the job would entail some tough love to prepare for the impending patent expiration for blockbuster multiple sclerosis drug Copaxone. I'm sure he never guessed polygraph tests would be involved, though. After leaks revealed a rift in management's relationship with the Board of Directors over implementing cost cuts, Levin allegedly subjected board members to polygraph tests to plug the leak. That's not particularly Foolish management, and not surprisingly Levin departed the company soon after.

Now Teva has a new head in CEO Erez Vigodman. Vigodman has a history of reforming unprofitable businesses and plans to continue Levin's cost cutting initiatives. The execution of this plan in the coming years is critical to boosting the company's profitability.

A Copaxone reprieve?
While Teva is known as one of the largest generic drug manufacturers, 20% of its third quarter revenue came from the branded drug Copaxone. That revenue comes with a much higher margin than Teva's generic offerings, and contributes much more to net income. That means that when Copaxone loses patent protection in May of this year, Teva could face a big hit to its top line, and an even bigger hit to its bottom line. So far, management has been unable to protect that revenue with a failed Supreme Court injunction and poor results for new MS drug Nerventra.

Last week, Teva and its shareholders received some uplifting news when the FDA approved a new, longer acting three-per-week dose of Copaxone, granting that formulation market exclusivity. Copaxone could still face generic competition for its once-daily injection, and Mylan is hot on the chase with a biosimilar version slated to hit shelves as soon as the patent expires. The biosimilar still requires FDA approval, but it could spell trouble for Teva if approved. This leaves the company only a few months to convert patients to the new formulation before a major pricing war kicks in.

That conversation is moot, though, if Biogen keeps rolling as it has been. Sales of the orally available multiple sclerosis drug Tecfidera have been crushing already lofty sales expectations. The drug brought in $876 million in its first year on the market, even while Biogen's other MS offerings Tysabri and Avonex continued to grow. Couple that with growth in other orally available drugs from Novartis and Sanofi, and Copaxone, even with an improved dosing schedule, could continue to lose market share.

The bottom line
New management could certainly bring life to the struggling company. If the new formulation of Copaxone can grasp market share before Mylan unrolls its biosimilar, then Teva should be able to stave off the competition. If not, the combination of generic and next-generation competition could wipe out revenue and earnings for some time.

Cost-cutting can soften the blow, but it can't carry the bottom line forever. The real goal for Teva should be to improve its generics pipeline, as growth of that sector has also stalled.

The Motley Fool's top stock pick for 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Seth Robey has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers